Penetrium Bioscience voting rights stake unchanged at 37.57% after pledge contract revision filing

Hyundai Bioscience filed an amended large-shareholding report in Penetrium, keeping its voting stake at 24,030,335 shares, or 37.57%. The update reflected a change in share-pledge arrangements, cutting shares under key contracts to 12,850,000 from 13,070,000. The disclosure was dated Oct. 14, 2026, with the obligation-trigger date listed as Sept. 21, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penetrium Bioscience Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261014000371), on October 14, 2026, and is solely responsible for the information contained therein. (C)